30.3 C
Vientiane
Sunday, July 20, 2025
spot_img
Home Blog Page 2411

OPPO Announces Winners of the 2022 OPPO Research Institute Innovation Accelerator and USD $460,000 Prize Fund

SHENZHEN, CHINA – Media OutReach – 29 August 2022 – OPPO today announced the ten winners of the inaugural OPPO Research Institute Innovation Accelerator. The OPPO Research Institute Innovation Accelerator has seen teams from around the world submit technology proposals aimed at tackling some of society’s biggest challenges. Following a three-month submission and judging process, the ten winning teams will share the RMB 3,000,000 (USD $460,000) prize fund and other resources provided by OPPO and its partners.

The winning teams of the OPPO Research Institute Innovation Accelerator

An earphone that can easily optimize sleep quality; a system designed to detect earthquakes early with rapid intensity reporting; and a smartphone specially designed to provide a greater quality of listening experience for hearing impaired — these are just some of the proposals submitted to this year’s OPPO Research Institute Innovation Accelerator. Launched in May this year, the Innovation Accelerator was established to support OPPO’s belief in “Virtuous Innovation” by seeking innovative proposals addressing key challenges in accessible technology and digital health. Over the three-month period, proposals were judged by a committee from OPPO Research Institute and partners. Proposals were judged against the four criteria of Feasibility, Innovation & Originality, Social Value, and Long-term Potential, with the following ten proposals being selected as the winners of this year’s program (displayed in no particular order):

  • Institute of Care-life/Chengdu Meihuan Technology Co., Ltd: A massive system designed to detect earthquakes early with rapid intensity reporting using IoT and AI.
  • Peking University Third Hospital: Detecting early-stage dementia through eye movements and other small indicators.
  • Lingxin Intelligence Co., Ltd: Combining AI and psychiatric treatment to provide effective and accessible mental health services.
  • Anhui Easpeed Technology Co., Ltd.: A project that can produce interactive images in free space without the need for an additional medium or screen.
  • Alango Technologies Limited: BeHear — An innovative hearing aid built from Bluetooth audio hardware and an exclusive hearing assistance algorithm.
  • Shenzhen Aibaowi Biotechnology Co., LTD: Tangtangquan — a diabetes digital therapeutic solution that works by providing an artificial pancreas and blood sugar monitoring system based on RTOS on a smart watch.
  • Zhejiang Nurotron Biotechnology Co.,Ltd: Hearing aid and Hearing Protect Technical solutions by supporting smart listening for people with cochlea implants.
  • Lyratone Technologies, Inc.: Lyratone hearing aid and hearing protection for hearing assistance.
  • Beijing Jadebird Vision Technology Co., ltd.: A machine vision solution for opticians and people with visual impairments.
  • IDUN Technologies AG: Sleep journey optimization platform by understanding brainwaves with EEG Hearables.

The ten winning proposals were selected from a total of 536 entries submitted by technology professionals, entrepreneurs, and social science researchers based in 39 countries and regions around the world. As part of the judging and selection process, demo events were held in Israel, India, and China. OPPO also made its debut appearance at VivaTech 2022 in France — Europe’s biggest startup and tech event — to promote the OPPO Innovation Accelerator and share its vision for a better and more inclusive future built on “Virtuous Innovation”.

Levin Liu, OPPO Vice President and President of the OPPO Research Institute

“Over the past few months, we have seen hugely innovative solutions that leverage the power of science and technology to address some of the biggest issues facing society right now,” said Levin Liu, OPPO Vice President and President of OPPO Research Institute. “As we continue to explore and push the boundaries of technology, we do so in alignment with our mission of ‘Technology for Mankind, Kindness for the World’. Through technological innovation, we want to help society develop in a positive direction and bring the benefits of Virtuous Innovation to more people. In the future, we look forward to working with more innovators to tackle key problems like these through the OPPO Research Institute Innovation Accelerator.”

With today’s most pressing challenges too big for any individual organization to tackle alone, OPPO established the OPPO Research Institute Innovation Accelerator to discover and develop technology that could help benefit those most in need of it. Following the announcement of the winners of this year’s Innovation Accelerator, OPPO will help the ten teams to further develop and promote their technologies by providing financial support, marketing resources, opportunities to apply their concepts in OPPO products, and exhibition of their ideas at global events.

Over the years, OPPO has built up vast experience in the areas of accessible technology and digital health, leveraging its understanding of user needs and insights to create tailored solutions for specific groups of users. For example, the OPPO Find X3 series includes a Color Vision Enhancement feature designed to improve the visual experience for those with color vision deficiencies. OPPO has also brought aging adaptation to its ColorOS operating system and smart products to enable elderly users to enjoy the benefits and convenience of technology. Further to this, OPPO has established the OPPO Health Lab to develop preventative health solutions designed to help users develop healthy lifestyle habits. In the future, OPPO will continue to develop its own technology and work with innovators worldwide to bring the benefits of technology to more people.

To learn more about the OPPO Research Institute Innovation Accelerator and this year’s winning proposals, please visit oppo.com/en/proposal/

Hashtag: #OPPO

About OPPO

OPPO is a leading global smart device brand. Since the launch of its first mobile phone – “Smiley Face” – in 2008, OPPO has been in relentless pursuit of the perfect synergy of aesthetic satisfaction and innovative technology. Today, OPPO provides a wide range of smart devices spearheaded by the Find X and Reno series. Beyond devices, OPPO also provides its users with ColorOS operating system and internet services such as OPPO Cloud and OPPO+. OPPO has footprints in more than 60 countries and regions, with more than 40,000 employees dedicated to creating a better life for customers around the world.

Uni-Bio Science Group Limited: 2022 Interim Results

Pinup® and Boshutai® Generated Remarkable Turnover while Achieving Record High Profit Aim to Build a Highly Commercial-Driven and Specialized R&D Platform

HONG KONG SAR – EQS Newswire – 29 August 2022 – A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its interim results for six months ended 30 June 2022 (the “Period”), as well as its comparative figures for six months ended 30 June 2021.

Key Accomplishments in the First Half of 2022

During the Period, the Group achieved a spectrum of accomplishments, for both of its marketed products and innovative biologics. The key highlights include:

1. During the Period, the Group’s recorded a turnover of approximately HK$195.6 million, representing a noticeable increase of 24.6% year-on-year (“YoY”). Sales of Pinup® and Boshutai® registered significant increase of 75.6% YoY and 410.2% YoY respectively.

2. The Group achieved a record high profit for the Period of approximately HK$14.6 million with a significant increase of 663.6% YoY. The profit was solely from its core operations and organic growth.

3. During the Period, the clinical work of Uni-GLP-1 injection pen was being accelerated. The Group also in preparation to the development of oral form Uni-GLP-1 to expand the value of the product and offer convenience to users.

4. The Group launched its new research center in Hong Kong and upgrade its business model to a “four-wheel drive” model, which included high-value generic drugs, bio-innovative drugs, CMO business and the newly introduced, advanced skincare raw materials. The Group has been building a highly commercial-driven and specialized boutique R&D platform, tightly integrating research and production under one roof.

5. During the Period, the marketing application of Bogutai® (teriparatide injection) was accepted by the China National Medical Products Administration (“NMPA”). Bogutai® is the Group’s fifth marketed drug and it is also the first domestic manufactured PTH Liquid in China to use a disposable injection pen. The Group strongly believes that Bogutai® will be a future blockbuster for the Group by virtue of the product’s strong cost advantage, better therapeutic effect and convenient administration method.

6. The Group’s Acarbose Tablets (Boshutai®) was successfully selected for Henan Thirteen Provinces Alliance Procurement with procurement validity period set at 2 years. This marked another milestone for the Company and has given the Group an opportunity to quickly expand the in-hospital market share. To satisfy the massive demand for Boshutai® going forward, the Group has already expanded its production capacity in its partner Suzhou production site to ensure its supply stability.

Interim Results

During the Period, the Group recorded a turnover of approximately HK$195.6 million, representing a significant increase of 24.6% year-on-year (first half of 2021: HK$157.0 million). The increase in turnover was mainly attributable to the remarkable sales growth of Pinup® and Boshutai®. Pinup® recorded a noticeable increase of 75.6% in turnover from approximately HK$56.1 million to approximately HK$98.5 million during the Period. The increase was attributable to Pinup®’s inclusion in the national centralized procurement in 2021, which has secured the Group with massive hospital orders. Turnover of Boshutai® increased substantially from approximately HK$1.3 million to approximately HK$6.5 million, representing a significant increase of 410.2%. GeneSoft® recorded an increase in turnover from approximately HK$17.2 million to approximately HK$17.8 million, representing an increase of 3.1%. Turnover generated from GeneTime® was approximately HK$72.7 million, representing a decrease of 11.7% from approximately HK$82.4 million in the first half of 2021. The production of GeneTime® was interrupted in the first quarter of 2022 due to the pandemic prevention and control measures implemented by the local government, resulting in the decrease of sales volume.

Gross profit was approximately HK$144.5 million, representing an increase of 16.1% as compared with approximately HK$124.4 million for the first half 2021, whereas gross profit margin was 73.9% (first half of 2021: 79.3%). The Group continued its strict control in general and administrative expenses, which only accounted for 12.1% of turnover for the Period as compared with 14.2% for the same period last year. The selling and distribution expense for the Period also decreased to 43.5% of turnover from 48.5% that of the same period last year partly due to the direct sales of GeneSoft® started with the Group’s self-developed, stable and efficient sales team since the second half of 2021. The Group’s sales team has greatly enhanced the distribution channel, promotion capability and efficiency of GeneSoft®. The R&D expenses increased by 13.8% to approximately HK$24.3 million as the Group continued to be research- and innovation-focused.

The Group recorded earnings before interest, tax, depreciation and amortization (“EBITDA”) for the Period of HK$27.6 million as compared to HK$13.1 million of the same period last year. Other revenue for the Period surged by 6,351.7% to approximately HK$5.6 million, which was mainly attributable to its growing CMO business. Despite of the Group’s continuous investment in R&D, its cash flow from operating activities for the Period remained positive. This reflects the Group’s strong capability to generate its own capital and support its major investments. The Group recorded a profit of approximately HK$14.6 million for the Period, representing a dramatically increase of 663.6% year-on-year (first half of 2021: HK$1.9 million). The increase in profit was mainly attributable to the impressive sales growth of GeneSoft®, Pinup® and Boshutai®, the increase in CMO business as well as the effective control of operating expenses. Basic earnings per share was approximately HK$ 0.23 cents (first half of 2021: HK$0.03 cents).

Prospects

China has introduced various regulatory reforms to promote the R&D development in the healthcare and biopharmaceutical sector. To ride on the favorable policies and capture the growing market opportunity, the Group has officially upgraded its business model to a “four-wheel drive” model, which includes high-value generic drugs, bio-innovative drugs, advanced skincare raw materials and CMO business, especially focusing on diabetes, ophthalmology, orthopedics and other therapeutic areas. With a new R&D centre set up in Hong Kong Science Park, the Group will be able to develop new innovative bio-products more quickly and efficiently, expand its product portfolio and reshape its R&D system, thus opening up new room for strategic growth.

Looking forward, Mr. Kingsley Leung, Chairman of Uni-Bio Science said, “We will adhere to our ‘strong R&D’ direction and continuously cultivate our internal strength. We have established short-to-long term goals to promote sustainable growth. In short term, our existing product lines will come to fruition. We expect our star products, GeneTime® and GeneSoft®, together with our two high-value generic drugs, Boshutai® and Pinup®, which have both successfully selected for centralized procurement, will continue to bring fast growing income to the Group. Besides the matured products, we will continue to explore the advanced skincare raw materials market. Leveraging our partner, Global Cosmetics’ extensive experience in the skincare industry, we have been working together on 5 functional raw materials, including collagen, fibronectin, beauty peptides, probiotics and exosomes. It’s also worth mentioning that the market application of Bogutai® (teriparatide injection) has been accepted by the NMPA in June 2022, meaning Bogutai® is likely to be the Group’s fifth marketed and self-developed drug. We believe that the launch of Bogutai® and advanced skincare raw materials will diversify our revenue stream, allowing us to enhance our profitability whilst decreasing our business risk going forward.

In medium term, we will diversify the outreach of EGF products while broadening ophthalmology products offerings. We would like to further extend the product life span of EGF products and develop different dosage forms of GeneTime® in order to bring greater convenience for our clients. In addition, we are planning to kick off the development of single dose form of GeneSoft® (no preservatives) utilizing a new Blowing Filling and Sealing (“BFS”) packaging technology, which will be safer and more convenient to use. The BFS packaging technology will also be used to produce Diquafosol Sodium Eye Drops, which is complementary to GeneSoft® and can generate synergy in sales.

In long term, we will continue to leverage the Group’s advanced scientific research technology, together with the innovative capabilities of our technology partners, we will continue to enhance our comprehensive R&D strength, diversifying our best-in-class drug portfolio while expanding business scope beyond. We will continue to actively expand the R&D channels, carry out multi-level R&D cooperations with different institutes to develop innovative biologic formulation technology, such as oral-peptide technology and CEPP, and explore new drug candidates using new antibody modalities. We particularly excited about the prospects of the oral GLP-1 and will accelerate the R&D progress, targeting to launch the product in the near future.”

Hashtag: #Uni-BioScience

About Uni-Bio Science Group Limited

Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development centre is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine such as diabetes and osteoporosis, ophthalmology and dermatology.

Uni-Bio Science Group Limited was listed on the Main Board of the Hong Kong Stock Exchange on November 12, 2001. Stock code: 0690.

Over 15,000 Cambodians Evacuate Following Fake Catastrophic Flood Prediction

Over 15,000 Cambodians gather at the politician's farm house.

A Cambodian politician’s prediction of a catastrophic flood prompted more than 15,000 panicked Cambodians to evacuate their homes and gather at a farmhouse south of Kulen mountain, Siem Reap province.

Asian Elephant Gives Birth to New Baby in Laos

A baby Asian elephant after its birth.

Mae Ping, an Asian elephant who had been pregnant for 22 months, finally gave birth to a calf at the Mekong Elephant Park in Xayaboury Province.

SonicWall Boosts Wireless Play with Ultra-High-Speed Wi-Fi 6 Access Points

New SonicWave 600 Series wireless access points, with Wi-Fi 6 technology, deliver always-on, always-secure connectivity for the most complex environments

SINGAPORE – Media OutReach – 29 August 2022 – SonicWall today announced the introduction of the new Wi-Fi 6 wireless security product line, which provides always-on, always-secure connectivity for complex, multi-device environments. Powered by Wi-Fi 6 technology, the new SonicWave 600 series wireless access points, coupled with Wireless Network Manager (WNM) 4.0, enable organizations to automatically secure wireless traffic while boosting performance and simplifying connectivity.

“In today’s hyper-connected world, organizations of all sizes are scaling high-performance wireless networks that need to be simple to deploy, dependable and secure,” said SonicWall President and CEO Bob VanKirk. “The SonicWave 600 series gives our global partner community and strategic MSSPs another solution to help protect their customers with secure, easy-to-manage wireless connectivity for the complex environments where they do business.”

SonicWall Wireless Network Manager (WNM) 4.0 provides an easy, effective way for enterprises, partners and MSSPs to securely manage wireless networks. WNM leverages the cloud to simplify management of complex environments with a unified, single-pane-of-glass cloud management portal.

The SonicWave 600 series uses Wi-Fi 6 technology which can increase overall wireless throughput by up to 4X compared to Wi-Fi 5 technology and reduce latency by up to 75%. Additionally, the SonicWave 600 series includes key features that address business needs for security, management, ease of deployment and scalability, including:

  • Increased wireless throughput by up to 4X. Superior Wi-Fi 6 performance using 802.11ax technology improves throughput, latency and total cost of ownership (TCO).
  • Ultra-fast wireless speeds on busy networks. Powered by Wi-Fi 6 technology, the SonicWave 600 series helps eliminate issues arising from crowded wireless networks while ensuring top speeds in highly dynamic environments.
  • Advanced cyberattack prevention. Increase confidence and block advanced cyberattacks with wireless access points integrated with the award-winning SonicWall Capture Advanced Threat Protection (ATP) sandbox service, patented Real-Time Deep Memory Inspection (RTDMI) and Reassembly-Free Deep Packet Inspection.
  • Threat detection and removal. Scan all wireless traffic coming into and going out of the network using deep packet inspection technology, and then remove harmful threats such as malware and intrusions, even over SSL/TLS-encrypted connections.
  • Reduced downtime. Never let a dropped or disrupted connection impact business, and safeguard revenue channels with secure, always-on connectivity for distributed networks.
  • Ability to build an optimized IoT environment. Design and scale high-performance networks capable of connecting dense, multi-device environments.
  • Upgrades along the way. Ensure consistency while improving performance and security by upgrading your environment — at your speed and within budget — to the latest technology that is fully backward-compatible.

“SonicWall has consistently provided solutions that have helped keep our campus secure over the years,” said Pam Messex, Chief Information Officer at Berean Baptist Church & Academy. “Educational environments have the challenge of being both secure and open simultaneously. Students need easy access to various resources, while staff members need to maintain secure records and safeguard personal information. Adding SonicWave wireless access points to our network gives us the ability to do this. We have come to rely on features such as segregation and security through client isolation, ease of use, and performance — especially as our campus becomes increasingly wireless.”

All SonicWave access points, including the new SonicWave 600 series, integrate with the cloud-delivered Wireless Network Manager 4.0, which allows for control and troubleshooting of wireless and switching access across networks of any size or region with a single pane of glass.

Designed with MSSPs in mind, the Wireless Network Manager infrastructure simplifies access, control and troubleshooting by unifying multiple tenants, locations and zones, while supporting thousands of SonicWave access points and SonicWall network switches — all without the cost of complex overlay management systems.

“The threat landscape evolves far too quickly to rely on legacy solutions,” said SonicWall Vice President of Products Jayant Thakre. “This advanced offering places additional emphasis on extending the performance of wireless networks with real-time threat mitigation. Businesses and their end users expect the best in real-time security, performance and analytics — regardless of the type of network or physical location.”

Debasish Mukherjee, Vice President, Regional Sales, Asia Pacific Japan at SonicWall added, “In today’s fast paced and increasingly connected world we live in, it’s only imperative that our environment remains secure yet open to new advancements. With the new SonicWave 600 series that uses Wi-Fi 6 technology, we can deliver always-on and always-secure connectivity even for the most complex environments. This means that end users can expect the best in real-time security, performance and analytics — to facilitate the management, ease of deployment and scalability of their operations regardless of the network or physical location they are in.”

The SonicWave 600 series will also be expanded with the release of SonicWave 621, currently scheduled for release by the end of calendar 2022.

To learn more about the SonicWave 600 series, please visit sonicwall.com/wireless.

Hashtag: #SonicWall

About SonicWall

SonicWall delivers Boundless Cybersecurity for the hyper-distributed era in a work reality where everyone is remote, mobile and unsecure. SonicWall safeguards organizations mobilizing for their new business normal with seamless protection that stops the most evasive cyberattacks across boundless exposure points and increasingly remote, mobile and cloud-enabled workforces. By knowing the unknown, providing real-time visibility and enabling breakthrough economics, SonicWall closes the cybersecurity business gap for enterprises, governments and SMBs worldwide. For more information, visit or follow us on , , and .

Phoutsavanh Vongkhamxao Crowned Miss Grand Laos 2022

Ms. Phoutsavanh Vongkhamxao, the winner of Miss Grand Laos 2022.

Phoutsavanh Vongkhamxao has been declared the winner of Miss Grand Laos 2022 and will go on to represent Laos at the Miss Grand International 2022 pageant in Indonesia this October.

SSY announces 2022 interim results

Net profit HK$570 million; Interim dividend HK$0.06/share
Seize development opportunities; Enhance competitive strength

Result summary:

  • Total revenue HK$3,405 million, representing a growth of 39.4%;
  • Net profit HK$570 million, representing a growth of 106.8%;
  • The Board resolved to pay interim dividend of HK$0.06 /share

HONG KONG SAR – Media OutReach – 29 August 2022 – SSY Group Limited (“SSY” or the “Company”; Stock Code: 2005.HK) and its subsidiaries (together, the “Group”) presents the interim results of the Company for the six months ended 30 June 2022.

During the first half of 2022, the Group achieved a revenue of HK$3,405 million, representing an increase of 39.4% compared to corresponding period of last year (“1H2021”) with gross profit margin 57.0%, representing a decrease of 3.2 percentage points compared to 1H2021. The Group achieved a net profit of HK$570 million, representing an increase of 106.8% compared to 1H2021.

Faced with pressure from continuous impacts of the epidemic, shrinking market demands and supply shock, the Group seized the development opportunities arising from changes in the industrial landscape and policy support, and implemented a series of measures to improve quality and enhance efficiency of its main business segments including preparations, bulk pharmaceuticals and medical materials, so as to maintain good growth momentum. Focusing on the dual circulation of domestic and international markets development pattern, the Group concentrated its efforts on market development for dominant preparations and key types of preparation products, and explored the domestic and overseas markets for its bulk pharmaceuticals and medical materials products. The Group also proactively optimised its product mix and placed great emphasis on the marketing of new featured products, leading to a new growth in market shares and sales volume.

The Board of directors proposed to pay an interim dividend of HK$0.06 per share for year 2022, which increased by 20% as compared to 1H2021. The total amount of interim dividend this year to be paid is approximately HK$179 million.

Amidst the normality under epidemic, the domestic pharmaceutical market witnessed a stable rigid demand. The Group continued to increase the market shares of the intravenous infusion solution and continuously solidified its leading position in the market. During the first half year, the sales volume of infusion solutions reached 754 million bottles (bags), representing an increase of 19.3% compared to 1H2021. Revenue of infusion solutions reached HK$1,834 million, representing an increase of 20% compared to 1H2021. Ampoule products delivered a remarkable market performance and have become a new support for the development of the Group’s injection segment. During the first half year, the revenue of ampoule products was HK$511 million, representing an increase of 4.7% compared to 1H2021, which maintained a good growth momentum. Solid preparations business segment delivered a steady and positive sales performance. In line with the national and local centralised procurement policies, the Group made coordinated efforts to secure market supply of tender-awarded products to promote and expand the market of new products. During the first half year, the revenue reached HK$145 million, representing an increase of 71% compared to 1H2021. Bulk pharmaceuticals business achieved a boost in both production and sales. After continuous optimization of production process, the premium production capacities were realised rapidly. In particular, as a vertical integration, the Group acquired Cangzhou Lingang Youyi Chemical Co., Ltd. at the beginning of the year, significantly improving the coordination between upstream and downstream entities of the industrial chain. During the first half of the year, revenue of bulk pharmaceuticals reached HK$777 million, representing an increase of 214.6% as compared to 1H2021. The Group achieved a growth jump in production and sale of medical materials. In the first half of the year, revenue from external customers of the Group recorded HK$90.55 million, representing an increase of 12.5% compared to 1H2021.

By using market demands as the guide and adhering to the strategy of “combination of generic and innovative drugs”, the Group made continuous and coordinated efforts to push forward the research and development of featured generic drugs, bulk pharmaceuticals, innovative drugs, medical materials as well as product types under consistency evaluation. The Group kept solidifying and expanding its strength in the research and development of featured generic drugs. During the first half of the year, a total of 22 production approvals were obtained, including 14 types of infusion products and 8 types of bulk pharmaceuticals, with the number of approvals obtained exceeding that of the whole year of 2021. So far, a total of 26 product types with 35 specifications of the Group have passed or were regarded as passing the national consistency evaluations regarding the quality and efficacy of generic drugs. During the period, 124 products of various types were also submitted by the Group to the Center for Drug Evaluation of the National Medical Products Administration for approval, including 100 preparation products (including products for consistency evaluation) and 24 types of bulk pharmaceuticals. The Group achieved positive progress in the Phase 1 clinical trial of the Type I innovative drug NP-01 project, and were stepping up efforts in the preparation of application materials for Phase 1 clinical trial for the innovative drug including ADN- 9, aiming to apply within the year. In addition, the bioprocessing film project of Jiangsu Best New Medical Material Co. Ltd. with an annual production capacity of 20 million square meters has completed construction and was ready for production on July 2022, providing a solid foundation for overall improvement of market supply capacity.

Looking forward to the second half of 2022, economic situation may remain severe and complicated amidst the normality under global epidemic. The Group will actively seize development opportunities and will make effort to facilitate the dual circulation of domestic and international markets in order to secure preemptive opportunities for development. On the preparations business, the Group will have an in-depth and a better systematic analysis on national and local centralized procurement policies, and will seize the market opportunities arising from the eighth round of National Centralised Medicines Procurement, with an aim to expand the market share and influence of its products passing the consistency evaluation. On the bulk pharmaceuticals business, the Group will proactively facilitate the domestic and international markets, and make efforts to strengthen and expand its bulk pharmaceuticals business, aiming to make a greater contribution to the development of the Group. In terms of research and development, the research and development of specialised generic drugs remains the focus of the Group’s research and development work for the moment. Facing the increasingly intensified competition in the research and development of generic drugs, the Company will leverage on the cooperation mechanism with universities and scientific research institutes, and explore more high quality research projects. The Group will continue to push forward proactively the spinoff listing of bulk pharmaceuticals segment in the PRC. At the same time, the Group will proactively seek opportunities of acquisition and investment in the pharmaceutical industry in order to increase the return on investment.

Mr. Qu Jiguang, Chairman and CEO of SSY said, “Facing the risks and challenges in the post-pandemic era, the Group will seize new opportunities for development in the industry. We will maintain the resilience and vitality of innovative development, and strive for facilitating the quality development of the Group. We firmly believe that, by virtue of the scale, quality, management and brand advantages accumulated in the industry over the years and the continuous innovation momentum released by the Group, we will strive to create new high record again in year 2022 in terms of production, sales and profit, and will bring satisfactory returns to our investors with a stronger result of development.”

Hashtag: #SSY

The issuer is solely responsible for the content of this announcement.

About SSY Group Limited

SSY Group Limited is one of the leading pharmaceutical manufacturers in China with nearly 7 decades of operation history and a well-established brand name. The Group went public on the Hong Kong Stock Exchange in December 2005 with stock code 2005. The Group is principally engaged in the research, development, manufacturing and selling of a wide range of pharmaceutical products, including finished medicines of mainly intravenous infusion solution and ampoule injection to hospitals and distributors, bulk pharmaceuticals and medical materials. The manufacturing plants of the Group locates in Hebei Province and Jiangsu Province in China, and its pharmaceutical products has leading position in the high-end hospital market in China.

Thailand Looks to Indian Weddings for New Tourism Revenue

Indian weddings in Thailand

Thailand is looking to Indian weddings as a new source of tourism following the loss of Chinese visitors this year.